Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. develops precision oncology diagnostics and data products centered on blood and tissue testing for cancer care. Company news commonly covers the Guardant360 liquid biopsy and Guardant360 Tissue franchises, Guardant Reveal for molecular residual disease monitoring, Shield colorectal cancer screening, and InfinityAI real-world data and analytics.
Recurring updates include financial results across Oncology, Screening, and Biopharma & Data revenue categories; FDA companion diagnostic approvals for Guardant360 CDx; research presentations in tumor typing, therapy selection, methylation and multiomic testing; and biopharma collaborations that use Guardant tissue and liquid biopsy assays to support targeted therapy development.
Guardant Health (Nasdaq: GH) and collaborators will present 38 abstracts, including an oral presentation with Pfizer, at the 2026 ASCO Annual Meeting. The data highlight liquid biopsy tests powered by InfinityAI, including Guardant360 Liquid CDx and the Shield blood test.
Key presentations cover pan-cancer companion diagnostics, enhanced ALK fusion detection in NSCLC, colorectal cancer screening, tissue-free MRD, and methylation-based tumor classification and tumor-of-origin prediction.
Guardant Health (Nasdaq: GH) announced that its FDA-approved Shield blood test is now recommended in updated American Cancer Society colorectal cancer screening guidelines. Shield is offered to average-risk adults 45+ who decline or have not completed stool-based or visual exams, aiming to improve screening participation.
Guardant Health (Nasdaq: GH) received FDA approval for Guardant360 Liquid CDx, described as the largest FDA-approved liquid biopsy panel. The test integrates genomic and epigenomic insights, offers a 100x wider genomic footprint than the prior Guardant360 CDx, and delivers results in as little as seven days.
According to Guardant Health, the approval transfers seven existing companion diagnostic indications, increases ctDNA detection sensitivity several-fold, and runs on its AI-enabled Smart Platform, supporting a unified liquid and tissue testing experience for advanced cancer care.
Guardant Health (Nasdaq: GH) announced inducement grants of restricted stock units to new employees under its 2023 Employment Inducement Incentive Award Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
The company granted RSUs for 143,898 shares to 267 new non-executive employees, vesting in three equal annual installments.
Guardant Health (Nasdaq: GH) reported Q1 2026 revenue of $301.7M, up 48% year-over-year, driven by Oncology, Biopharma & Data, and Shield screening. The company raised 2026 revenue guidance to $1.30–$1.32B and expects Shield volume of 230k–245k tests.
Q1 non-GAAP gross margin was 66%, operating expenses rose, net loss was $112.1M, and cash and equivalents were $1.2B as of March 31, 2026.
Guardant Health (Nasdaq: GH) announced FDA approval of Guardant360 CDx as a companion diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) on May 4, 2026. The blood-based liquid biopsy detects ESR1 mutations in ER+/HER2- advanced or metastatic breast cancer after prior endocrine therapy.
The approval enables a non-invasive method to identify patients eligible for VEPPANU, marks Guardant's third ESR1 companion diagnostic, and is the platform's 26th companion diagnostic indication with coverage for >300 million lives.
Guardant Health (Nasdaq: GH) announced a multi-year global collaboration with Nuvalent (Nasdaq: NUVL) to use Guardant’s tissue and liquid biopsy portfolio, including the Guardant Infinity™ platform, to support Nuvalent clinical studies and evaluate companion diagnostic (CDx) development and potential joint commercialization.
The partnership will: use Guardant tissue and liquid tests in certain Nuvalent global trials; assess Guardant assays as potential CDx for Nuvalent investigational candidates; and collaborate on global commercialization of Nuvalent therapies and Guardant CDx if approvals occur.
Guardant Health (Nasdaq: GH) will participate in three investor conferences in May–June 2026, including fireside chats and a presentation.
Events: BofA Securities Healthcare Conference (May 12, 10:40 a.m. PT), William Blair Growth Stock Conference (June 2, 9:20 a.m. CT), and Jefferies Global Healthcare Conference (June 3, 11:05 a.m. ET). Live and archived webcasts will be available on the company website.
Guardant Health (Nasdaq: GH) will report first quarter 2026 financial results after market close on Thursday, May 7, 2026. Management will host a webcast and conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Live audio will be available on the company’s Investors webpage and archived for replay after the event.
Guardant Health (Nasdaq: GH) said real-world evidence from its InfinityAI platform supported Japan approval of ENHERTU (trastuzumab deruxtecan) for previously treated HER2-positive advanced or recurrent solid tumors.
The MHLW approval was supported by clinical trial data plus supplemental RWE from InfinityAI and Guardant360, supplied in collaboration with Daiichi Sankyo.